Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1978 1
1983 1
1984 1
1987 2
1989 1
1991 1
1992 2
2002 1
2010 1
2011 1
2013 3
2014 4
2015 1
2016 3
2017 3
2018 5
2019 3
2020 5
2021 8
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

42 results
Results by year
Filters applied: . Clear all
Page 1
Rare Nivolumab-associated Super Hyper Progressive Disease in Patients With Advanced Gastric Cancer.
Kubota Y, Yoshimura K, Hamada K, Hirasawa Y, Shida M, Taniguchi M, Matsui H, Ariizumi H, Ishiguro T, Suzuki N, Ohkuma R, Sambe T, Ishida H, Horiike A, Wada S, Tsurutani J, Iwamoto S, Uchida N, Kiuchi Y, Kobayashi S, Tsunoda T. Kubota Y, et al. Among authors: ohkuma r. In Vivo. 2021 May-Jun;35(3):1865-1875. doi: 10.21873/invivo.12449. In Vivo. 2021. PMID: 33910874 Free PMC article.
Episode-based cost reduction for endovascular aneurysm repair.
Itoga NK, Tang N, Patterson D, Ohkuma R, Lew R, Mell MW, Dalman RL. Itoga NK, et al. Among authors: ohkuma r. J Vasc Surg. 2019 Jan;69(1):219-225.e1. doi: 10.1016/j.jvs.2018.04.043. Epub 2018 Jun 28. J Vasc Surg. 2019. PMID: 30185384 Free PMC article.
Antibiotic Usage Reduced Overall Survival by over 70% in Non-small Cell Lung Cancer Patients on Anti-PD-1 Immunotherapy.
Hamada K, Yoshimura K, Hirasawa Y, Hosonuma M, Murayama M, Narikawa Y, Ariizumi H, Ohkuma R, Shida M, Kubota Y, Matsukuma S, Ishiguro T, Sambe T, Horiike A, Kuramasu A, Wada S, Tsurutani J, Inoue E, Uchida N, Kiuchi Y, Kobayashi S, Hoffman RM, Tsunoda T. Hamada K, et al. Among authors: ohkuma r. Anticancer Res. 2021 Oct;41(10):4985-4993. doi: 10.21873/anticanres.15312. Anticancer Res. 2021. PMID: 34593446
Increased Plasma Soluble PD-1 Concentration Correlates with Disease Progression in Patients with Cancer Treated with Anti-PD-1 Antibodies.
Ohkuma R, Ieguchi K, Watanabe M, Takayanagi D, Goshima T, Onoue R, Hamada K, Kubota Y, Horiike A, Ishiguro T, Hirasawa Y, Ariizumi H, Tsurutani J, Yoshimura K, Tsuji M, Kiuchi Y, Kobayashi S, Tsunoda T, Wada S. Ohkuma R, et al. Biomedicines. 2021 Dec 16;9(12):1929. doi: 10.3390/biomedicines9121929. Biomedicines. 2021. PMID: 34944745 Free PMC article.
Minimal contribution of the hepatic uptake transporter OATP1B1 to the inter-individual variability in SN-38 pharmacokinetics in cancer patients without severe renal failure.
Tsuboya A, Kubota Y, Ishida H, Ohkuma R, Ishiguro T, Hirasawa Y, Ariizumi H, Tsunoda T, Sasaki Y, Matsumoto N, Kondo Y, Tomoda Y, Kusuhara H, Fujita KI. Tsuboya A, et al. Among authors: ohkuma r. Cancer Chemother Pharmacol. 2021 Sep;88(3):543-553. doi: 10.1007/s00280-021-04314-1. Epub 2021 Jun 11. Cancer Chemother Pharmacol. 2021. PMID: 34117512
High expression of olfactomedin-4 is correlated with chemoresistance and poor prognosis in pancreatic cancer.
Ohkuma R, Yada E, Ishikawa S, Komura D, Ishizaki H, Tamada K, Kubota Y, Hamada K, Ishida H, Hirasawa Y, Ariizumi H, Satoh E, Shida M, Watanabe M, Onoue R, Ando K, Tsurutani J, Yoshimura K, Yokobori T, Sasada T, Aoki T, Murakami M, Norose T, Ohike N, Takimoto M, Izumizaki M, Kobayashi S, Tsunoda T, Wada S. Ohkuma R, et al. PLoS One. 2020 Jan 10;15(1):e0226707. doi: 10.1371/journal.pone.0226707. eCollection 2020. PLoS One. 2020. PMID: 31923206 Free PMC article.
A high number of PD-L1+ CD14+ monocytes in peripheral blood is correlated with shorter survival in patients receiving immune checkpoint inhibitors.
Ando K, Hamada K, Shida M, Ohkuma R, Kubota Y, Horiike A, Matsui H, Ishiguro T, Hirasawa Y, Ariizumi H, Watanabe M, Onoue R, Tsurutani J, Yoshimura K, Tsunoda T, Kobayashi S, Wada S. Ando K, et al. Among authors: ohkuma r. Cancer Immunol Immunother. 2021 Feb;70(2):337-348. doi: 10.1007/s00262-020-02686-6. Epub 2020 Aug 5. Cancer Immunol Immunother. 2021. PMID: 32757055
42 results